Avian Influenza Vaccine Market to Reach USD 2.19 Billion by 2034

The Global Avian Influenza Vaccine Market is witnessing accelerated growth due to increasing global poultry production, recurrent avian flu outbreaks, and government-led vaccination campaigns. According to Exactitude Consultancy, the market, valued at USD 1.34 billion in 2024, is projected to reach USD 2.19 billion by 2034, growing at a CAGR of 5.0 % during 2025-2034.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49897

Rising concerns over zoonotic transmission, trade losses, and food security have positioned avian influenza vaccination as a critical component of animal health management across Asia, Europe, and the Americas.

Key Takeaways
• Market Size: USD 1.34 billion (2024) → USD 2.19 billion (2034)
• CAGR: 5.0 % (2025-2034)
• Dominant Vaccine Type: Inactivated vaccines hold over 60 % of market share
• Emerging Trend: Development of recombinant and vector-based vaccines for long-term immunity
• Leading Regions: Asia-Pacific leads the market; Europe shows strong regulatory support

Market Story
Avian influenza (AI), commonly known as bird flu, continues to threaten global poultry populations, affecting both commercial farms and backyard production systems.
To mitigate the economic and public health impact, governments and poultry producers are increasing adoption of preventive vaccination strategies in combination with enhanced biosecurity measures.

Traditional inactivated virus vaccines remain the backbone of disease control programs. However, next-generation recombinant and vector-based vaccines are gaining traction for their ability to induce broad, cross-protective immunity and facilitate differentiation of infected from vaccinated animals (DIVA) strategies.

The growing frequency of highly pathogenic avian influenza (HPAI) outbreaks and the rise in industrial-scale poultry farming are further accelerating vaccine demand.

Segmentation Overview
By Vaccine Type
• Inactivated Vaccines
• Recombinant Vaccines
• Vector-Based Vaccines
• Live Attenuated Vaccines

By Strain Type
• H5 Strain
• H7 Strain
• H9 Strain
• Others

By Application
• Poultry (Broilers, Layers, Breeders)
• Waterfowl (Ducks, Geese)
• Others

By Distribution Channel
• Veterinary Clinics
• Government Programs
• Private Poultry Farms

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/49897/avian-influenza-vaccine-market

Recent Developments
• Ceva Santé Animale expanded production of Vectormune® AI, a recombinant vector vaccine covering H5 and H7 strains.
• Zoetis Inc. launched new multivalent vaccines integrating avian influenza and Newcastle disease protection.
• Merial (Boehringer Ingelheim Animal Health) continued global distribution of Gallimune® range for broad-spectrum poultry protection.
• Harbin Veterinary Research Institute (China) developed recombinant H5+H7 strain vaccines, supported by government programs.
• Elanco Animal Health announced investments in vaccine R&D to combat emerging HPAI variants.

Expert Quote
"Avian influenza vaccination is no longer optional-it's an essential pillar of global food security.
With advances in recombinant and vector-based vaccines, producers can now achieve broader immunity and sustainable disease control,"
said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=49897

Market Drivers
• Increasing frequency of avian influenza outbreaks worldwide
• Rising government support for mass vaccination programs
• Advancements in recombinant and vector vaccine technology
• Growing global poultry meat and egg production
• Expanding focus on animal health surveillance and traceability

Forecast and Outlook
Between 2025 and 2034, the avian influenza vaccine market will evolve toward universal and recombinant formulations capable of addressing multiple viral strains.
Advancements in AI-based epidemiological modeling, rapid vaccine production platforms, and cold chain logistics optimization will enhance responsiveness to new outbreaks.

Asia-Pacific will remain the largest market due to high poultry density and frequent virus recurrence. Europe and North America are expected to adopt innovative DIVA-compatible vaccines to balance disease control with trade policies.

Regional Insights
• Asia-Pacific: Dominant market; widespread vaccination campaigns in China, India, and Indonesia.
• Europe: Strong R&D and regulatory harmonization supporting rapid vaccine approvals.
• North America: Focus on biosecurity integration and export-oriented vaccine production.
• Latin America: Growing poultry export markets increasing preventive vaccination needs.
• Middle East & Africa: Rising vaccination adoption due to disease surveillance initiatives.

Conclusion
The Global Avian Influenza Vaccine Market stands at the crossroads of biotechnology and food security.
As outbreaks become more frequent and economic stakes rise, innovation in next-generation vaccines and real-time monitoring systems will be critical for sustainable poultry health management.

Manufacturers investing in recombinant platforms, scalable production, and international collaborations are best positioned for the next phase of global growth.

This report is also available in the following languages : Japanese (鳥インフルエンザワクチン市場), Korean (조류 인플루엔자 백신 시장), Chinese (禽流感疫苗市场), French (marché des vaccins contre la grippe aviaire), German (Markt für Vogelgrippeimpfstoffe), and Italian (Mercato dei vaccini contro l'influenza aviaria), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/49897

Related Reports

U.S. Avian Influenza Vaccine Market
https://exactitudeconsultancy.com/reports/50377/u-s-avian-influenza-vaccine-market

Poultry Vaccines Market
https://exactitudeconsultancy.com/reports/61449/global-poultry-vaccines-market

Antiserum Market
https://exactitudeconsultancy.com/reports/64211/global-antiserum-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.